Spain
Oryzon Genomics SA, founded in 2000 and headquartered in Spain, is a clinical stage biopharmaceutical leader in the development of epigenetics-based therapeutics, with an emphasis on personalized medicine for CNS disorders and oncology. Known for its slogan, "Pioneering personalized medicine in epigenetics," the company maintains a broad portfolio.
Currently, Oryzon has two key compounds in clinical trials: iadademstat, targeting acute myeloid leukemia and small cell lung cancer in Phase IIa, and vafidemstat, a CNS-optimized inhibitor in multiple Phase II trials for CNS and psychiatric diseases. Preparations for Phase IIb trials are underway. Their pipeline also includes ORY-3001 in preclinical development for non-oncological diseases.
Publicly listed on the Spanish Stock Exchange since December 2015 (ticker: ORY), Oryzon has gained backing from specialized investors across US, Israel, and Europe through several PIPEs. The most recent funding, a $498.69K grant, was received from The ALS Association on 04 December 2023.
